|
Chugai Pharmaceutical Co., Ltd. is a pharmaceutical company that develops, manufactures, and sells prescription drugs. Its domestic operations involve selling manufactured medicines through a network of exclusive distributors, with some raw materials sourced from F. Hoffmann-La Roche Limited and manufacturing outsourced to Chugai Seiyaku Kogyo Co., Ltd. and Genentech, Inc. Research and clinical development activities are partially delegated to Chugai Medical Science Research Institute and Chugai Clinical Research Center. Internationally, the company operates through subsidiaries including Chugai Pharma Europe Limited, Chugai Pharma UK Limited, Chugai Pharma France SAS, and Chugai Pharma Germany GmbH for sales in Europe, while Chugai Pharma USA Inc. handles development and regulatory affairs in the United States. In Asia, the company sells products through Chugai Pharmaceutical Co., Ltd. in Taiwan and Nisshin Chugai Pharmaceutical Co., Ltd. in China, with production in China managed by Taizhou Nisshin Chugai Pharmaceutical Industry Co., Ltd. The group also engages in venture capital investments through Chugai Venture Fund LLC and Chugai Venture Fund LP. In late 2025, the company acquired and merged with Renalis Pharma Co., Ltd. Summarised from the annual report, fiscal year ended Dec 2025 |
Industry Drug Manufacturers - General | Homepage chugai-pharm.co.jp |
| Sector Healthcare | IR page chugai-pharm.co.jp | |
|
Tags
prescription drugs, oncology, cardiovascular, pharmaceutical manufacturing, clinical research, venture capital, pharmaceutical distribution, F. Hoffmann-La Roche Limited, Chugai Seiyaku Kogyo Co. Ltd., Genentech Inc., Chugai Medical Science Research Institute, Chugai Clinical Research Center, Chugai Seiyaku Business Solution Co. Ltd., Chugai Pharma Europe Limited, Chugai Pharma UK Limited, Chugai Pharma France SAS, Chugai Pharma Germany GmbH, Chugai Pharmaceutical Co. Ltd. (Taiwan), Nisshin Chugai Pharmaceutical Co. Ltd., Taizhou Nisshin Chugai Pharmaceutical Industry Co. Ltd., Chugai Pharma USA Inc., Chugai Pharma Body Research Pte. Ltd., Chugai Venture Fund LLC, Chugai Venture Fund LP, Renalis Pharma Co. Ltd.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 10.236T |
| Market cap (USD) | $ 63.973B |
| P/E | 19.92 |
| PEG | 3.95 |
| P/BV | 4.90 |
| P/S | 7.24 |
| P/OCF | 26.50 |
| P/FCF | 37.26 |
| Dividend yield | 4.5% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 22.1% |
| ROI | 21.4% |
| ROIC | 21.5% |
| Profit margin | 34.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 5.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 61 |
| Quality score | 21.1% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.258T | 1.171T | 1.111T | 1.26T | 999.759B | 786.946B | 686.184B | 579.787B | 534.199B | 491.78B | 498.839B | 461.109B | 426.003B | 391.22B |
| Net profit | 434.012B | 387.317B | 325.472B | 374.429B | 302.995B | 214.733B | 157.56B | 92.488B | 72.713B | 53.592B | 61.125B | 50.98B | 50.615B | 48.205B |
| Free cash flow | 274.673B | 393.211B | 337.977B | 172.873B | 213.657B | 147.995B | 153.632B | — | — | — | — | — | — | — |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 8.243K | 6.998K | 5.342K | 3.369K | 3.736K | 5.503K | 10.079K | 6.379K | 5.77K | 3.355K | 4.24K | 2.964K | 2.325K | 1.651K |
| Price performance 12m | 0.18 | 0.31 | 0.59 | -0.1 | -0.32 | -0.45 | 0.58 | 0.11 | 0.72 | -0.21 | 0.43 | 0.27 | 0.41 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | — | — | 180B | 182B | 253B | 355B | 513B | 319B | 334B | 443B |
| ↳ YoY growth | +1.2% | +39.5% | +40.2% | +44.3% | -37.8% | +4.8% | +32.5% | |||
| ↳ 5y CAGR | +12.2% | +13.0% | +11.8% | |||||||
| Cash and deposits (JPY) | 95.4B | 139B | 147B | 204B | 212B | 268B | 222B | 459B | 540B | 427B |
| Intangible assets (JPY) | — | — | 22.7B | 23.5B | 23.9B | 22B | 25.1B | 19.9B | 17.9B | 54.5B |
| Right-of-use assets (JPY) | — | — | — | 9.75B | 8.27B | 13.3B | 11.3B | 10.8B | 8.43B | 22.9B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 38.8B | 108B | 119B | 207B | 205B | 280B | 244B | 410B | 448B | 386B |
| Purchases of property, plant and equipment (JPY) | — | — | -71.8B | -53B | -57B | -66B | -62.6B | -71.9B | -50.4B | -76.3B |
| Purchases of intangible assets (JPY) | — | — | -5.89B | -8.17B | -4.35B | -6.9B | -8.61B | -2.31B | -3.97B | -35.3B |
| Dividends paid (cash effect) (JPY) | — | — | -35B | -56.4B | -91.4B | -98.6B | -138B | -132B | -133B | -299B |
| Income taxes paid (cash effect) (JPY) | — | — | -31.6B | -34.8B | -66.8B | -104B | -152B | -176B | -100B | -191B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | — | — | 41.4B | 145B | 144B | 207B | 173B | 336B | 393B | 275B |
| Income detail | ||||||||||
| Research and development expense (JPY) | — | — | 99.2B | 102B | 114B | 130B | 144B | 163B | 177B | 180B |
| ↳ 5y CAGR | +10.4% | +11.6% | +9.7% | |||||||
| Total comprehensive income (JPY) | 51.1B | 76.1B | 87.6B | 155B | 217B | 306B | 374B | 332B | 409B | 423B |
| Comprehensive income to owners (JPY) | 50.4B | 75.2B | 87.1B | 155B | 217B | 306B | 374B | 332B | 409B | 423B |
| Reported | Mar 23, 2017 | Mar 22, 2018 | Mar 30, 2020 | Mar 23, 2021 | Mar 23, 2021 | Mar 29, 2022 | Mar 30, 2023 | Mar 28, 2024 | Mar 27, 2025 | Mar 25, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
News Release
202 6 年 10 月 27 日 各
位
202 6 年 12 月期第 3 四半期連結決算 中外製薬株式会社(本社:東京、代表取締役社長
CEO:奥田修)は、本日、 202 6 年 12 月
期第 3 四半期連結決算を発表しました。
Core 売上収益は 10,681 億円(前年同期比 17.2 %増) 、 Core 営業利益は 5,361 億円(同 19.0 %増) 、 Core 四半期利益は 3,847 億円(同 20.2 %増) となり、前年同期比で増収増 益。通期予想に対し、過達を見込 む
製商品売上高は、 NEMLUVIO ®とアレセンサ
®
輸出の増加や国内の主力品および新製品が増
加。 なお、次世代基幹業務基盤( ERP) の稼働に向けた移行対応として、
国内の出荷時期を
前倒し たこと により 、国内製商品売上高が増加。 その他の売上収益も ヘムライブラ
®
、
NEMLUVIO のロイヤルティ収入 に加え、一時金収入により 増加
研究開発活動は、自社創製品 を はじめ とする 開発早期・後期 で着実に進捗
®
独自の抗体エンジニアリング技術を用いたエンスプリング
について、甲状腺眼症
( TED)に対し 、米国食品医薬品局( FDA) が承認
世界的権威のある ラスカー・ドゥベーキー臨床医学研究賞 製を主導した 血友病 A 治療薬ヘムライブラについて、 し たオートインジェクター
emugrobart
を受賞した当社研究者が創
治療負担のさらなる軽減を目指
製剤を 国内外で 2027 年に上市を 目指す
について、 ロシュからのライセンス返還を
予定。 また 、脊髄性筋萎縮症
( SMA) に対し、第三者への導出も含め自社開発再開に向け て準備を開始
ルンスミオ ®の再発又は難治性濾胞性リンパ腫、 セーファキセルセン の IgA 腎症を対象 とした第 III 相試験において、 いずれも 中間解析時点において 主要評価項目を達成
自社創製品の DONQ52 について 、セリアック病を対象
とした 第 Ia/b 相試験および 第
Ic 相試験における Biological PoC 結果を 11 月の ICDS 2026 ( International Celiac Disease Symposium
)にて発表予定
決算の詳細については、以下をご覧ください。 決算短信・補足資料 https://www.chugai
-pharm.co.jp/ir/reports_downloads/tanshin.html
決算説明会資料 当社の業績動向に加え、研究開発パイプラインの進捗等を よびスクリプトを掲載します。 https://www.chugai
-pharm.co.jp/media/conference.html
ご 確認いただけます。後日、動画お
【 20 26 年 12 月期 1-9 月実績】
Core 実績【億円】 売上収益
202 6 年
202 5 年
1-9 月
1-9 月
前年同期比
10,681
9,116
+17.2 %
国内製商品売上高
4,063
3,437
+18.2 %
海外製商品売上高
5,005
4,509
+11.0 %
その他の売上収益
1,613
1,171
+37.7 %
営業利益
5,361
4,505
+19.0 %
四半期利益
3,847
3,200
+20.2 %
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Chugai Pharmaceutical Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| OZEM | 7.20% | 87,300 | $ 4.023M | Nov 17, 2026 |
| CGIE | 1.19% | 628,100 | $ 29.066M | Nov 16, 2026 |
| HRTS | 1.07% | 13,731 | $ 594.193K | Aug 31, 2026 |
| RFDI | 0.63% | 24,100 | $ 1.05M | Jul 31, 2026 |
| CGGE | 0.36% | 252,900 | $ 11.703M | Nov 16, 2026 |
| DIHP | 0.26% | 390,800 | $ 17.47M | Nov 12, 2026 |
| UMMA | 0.24% | 16,627 | $ 719.762K | Aug 31, 2026 |
| CGIC | 0.18% | 96,500 | $ 4.466M | Nov 16, 2026 |
| NTSI | 0.17% | 18,200 | $ 843.678K | Jun 30, 2026 |
| DFSI | 0.12% | 32,300 | $ 1.444M | Nov 12, 2026 |
| DFAI | 0.11% | 439,800 | $ 19.66M | Nov 12, 2026 |
| AVSD | 0.08% | 6,900 | $ 315.77K | Nov 16, 2026 |
| AVDE | 0.06% | 256,400 | $ 11.734M | Nov 16, 2026 |
| DXIV | 0.06% | 3,100 | $ 138.579K | Nov 12, 2026 |
| DFIC | 0.06% | 197,800 | $ 8.842M | Nov 12, 2026 |
| JSTC | 0.04% | 2,283 | $ 105.584K | Nov 17, 2026 |
| DFAX | 0.03% | 91,200 | $ 4.077M | Nov 12, 2026 |

